



FRIDAY 4 AUGUST

7.45 - 8.40am

Breakfast Session (Catered)

Level 2, Meeting Room 6

Head and Neck Cancer

Prof Pablo Fernandez-Penas - Cutaneous Toxicities-EGFR, Immunotherapy and Chemotherapy

Dr Annette Lim - Systemic Treatment in Head and Neck Cancers

Chair: Dr Bella Nguyen



8.40 - 10.00am

Highlight Session

Level 3, BelleVue Ballroom 2

Kidneys, Cardiolo-Oncology and Controlling Kryptonite

Mrs Liesel Byrne - eviQ Renal Dosing Guidelines Update

Dr Andrew McLean-Tooke - Controlling Kryptonite - Quietening the Overstimulated immune System - The Immunologist Perspective

Dr Piyush Grover - Overcoming Kryptonite - Controlling the Overstimulated Immune System - The Medical Oncologist Perspective

Chair: Prof Desmond Yip

10.00 - 10.30am

Morning Tea

Level 3, BelleVue Ballroom 1

10.30 - 11.30am

Oral Session - Young Oncologists

Level 3, BelleVue Ballroom 2

- Retrospective Analysis of Clinical Characteristics and Outcomes of Patients with Carcinoma of Unknown Primary from Three Tertiary Centres in NSW - Dr Emma Boys
- A Cross-sectional Analysis of Phase 1 Oncology Trials in Australia 2012-2022 - Dr Sathya Manoharan
- Registry-based Cancer Clinical Trials – A Pragmatic Approach to Efficiently Address Routine Clinical Questions - Dr Vanessa Wong
- Real-world Outcomes and Patterns of Care in Patients with “wild-type” NSCLC and Brain mMetastases: A National Multicentre Study - Dr Lauren Brown
- CONSENT: RCT of Enhanced Informed Consent to Improve Patient Understanding of Phase 1 Trials (NCT04407676) – Trial Comprehension Domain Analysis - Dr Abhijit Pal

Co-Chairs: Dr Anna Mislant and Dr Hilda High

11.30am - 12.40pm

Symposium 3

Level 3, BelleVue Ballroom 2

Challenging Toxicities in Oncology

Prof Janette Vardy - Neuropathy

A/Prof Matteo Lambertini - Fertility

Prof Pablo Fernandez-Penas - Mucositis Management

Chair: Dr Kim Kennedy

12.40 - 1.30pm

Lunch

Level 3, BelleVue Ballroom 1

1.30 - 2.30pm

Oral Session - Consultants

Level 3, BelleVue Ballroom 2

- Estimating Survival Scenarios in Advanced Oesophageal and Gastric (AOG) Adenocarcinoma Treated with Systemic Therapy: Systematic Review of Randomised-controlled Trials (RCT) - Dr Sayeda Naher
- Real-world Outcomes and Health-related Quality of Life (HRQoL) in Patients with Melanoma in Australia Receiving Adjuvant Nivolumab - Prof Victoria Atkinson
- Cancer Clinical Trials in Australia in the Pre- and Post- Covid-19 Era - A/Prof Tim Clay
- A Combination of PD-1/TIGIT Immune Checkpoint Inhibitors Elicits a Strong Anti-tumour Response in the Mouse Pleural Mesothelioma Model - A/Prof Steven Kao
- Two-year RELATIVITY-047 Results with NIVO+RELA FDC Versus NIVO in Previously Untreated Metastatic or Unresectable Melanoma - Prof Victoria Atkinson

Chair: A/Prof Connie Diakos

2.30 - 3.30pm

Symposium 4

Level 3, BelleVue Ballroom 2

Common Sense in Oncology Research

Dr Deme Karikios - Introduction - What is Common Sense?

A/Prof Bishal Gyawali - Common Sense in Oncology - Hits and Misses So Far

Dr Tam Bui - Common Sense in a Clinical Trial Program

3.30 - 4.00pm

Afternoon Tea

Level 3, BelleVue Ballroom 1

4.00 - 5.00pm

Clinician Wellbeing

Level 3, BelleVue Ballroom 2

A/Prof Matteo Lambertini - Rising From the COVID 19 Pandemic - Lessons on Clinician Resilience and Wellbeing

A/Prof Tom John - The Art of Flying while Falling

Chair: Dr Deme Karikios

5.00 - 6.00pm

Networking Function

Level 3, BelleVue Ballroom 1

Prof M. Tattersall Heroes Award Announcement - 2023 Award Recipient: Ms Kay Francis

Co-Chairs: Dr Chandra Diwakarla and A/Prof Tim Clay

